|
|
clinical Observation of Nerve Growth Factor on the treatment of Acquired Paralytic Strabismus |
Chunjie Mao,Jingkai Zhang,Hua Yan |
Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin 300052, China |
|
|
Abstract Objective: To observe the effects of nerve growth factor (NGF) on the treatment of acquired paralytic strabismus. Methods: In this prospective clinical study, 73 patients with acquired paralytic strabismus were reviewed between January 2012 to December 2014 at Tianjin Medical University General Hospital.They were divided into 2 groups depending on whether or not NGF was used. There were 45 patients in the combined NGF group and 28 in the semplice mecobalamin group. Conservative treatment was used in the two groups. Patients in the combined NGF group were injected intramuscularly with 18 μg of NGF and 500 μg of mecobalaminonce a day for 4 weeks. Those in the semplice mecobalamin group were injected by the same method with 500 μg of only mecobalaminonce a day for 4 weeks. Curative effects were estimated at the end of treatment and 3 months after treatment. Differences between the two groups were determined using chi-square tests. results: There was a significant difference in the cure rate and effective rate between the 2 groups at the end of treatment (cure rate: 67% vs. 43%, effective rate: 89% vs. 68%) ( χ 2 =4.005,P=0.045; χ 2 =4.926, P=0.026), and 3 months after treatment (cure rate: 87% vs. 46%, effective rate: 98% vs. 75%) ( χ 2 =13.638, P<0.001; χ 2 =9.177, P=0.002). In addition, the cure rate in the combined NGF group at 3 months after treatment was significantly higher than at the end of treatment (P=0.001). There was no significant difference at 3 months for the semplice mecobalamin group (P=0.711). conclusions: The curative effect of mecobalamin with NGF is superior to semplice mecobalamin alone for the treatment of acquired paralytic strabismus. In addition, the NGF treatment has long-term effects.
|
Received: 11 April 2018
|
Fund: National Natural Science Foundation of China (81670865, 81500743); Tianjin Science and Technology Support Program (13ZCZDSY02400) |
Corresponding Authors:
Hua Yan, Department of Ophthalmology, Tianjin Medical University General Hospital,Tianjin 300052, China (Email: phuayan2000@163.com)
|
|
|
|
[1] |
Ho TH, Lin HS, Lin MC, et al. Acquired paralytic strabismus in Southern Taiwan. J Chin Med Assoc, 2013, 76(6): 340-343.DOI: 10.1016/j.jcma.2013.03.003.
|
[2] |
赵堪兴, 杨培增. 眼科学. 8版. 北京: 人民卫生出版社, 2013:277-278.
|
[3] |
张小红. 甲钴胺在麻痹性斜视中的效果和安全性观察. 中国医疗前沿, 2012, 7(11): 56-57. DOI: 10.3969/j.issn.1673-5552.2012.11.0034.
|
[4] |
付景珂, 唐艳辉, 赵霞. 弥可保穴位注射治疗后天性麻痹性斜视临床观察. 中国斜视与小儿眼科杂志, 2010, 18(2): 88-89,92. DOI: 10.3969/j.issn.1005-328X.2010.02.015.
|
[2] |
赵堪兴, 杨培增. 眼科学. 8版. 北京: 人民卫生出版社, 2013:277-278.
|
[3] |
张小红. 甲钴胺在麻痹性斜视中的效果和安全性观察. 中国医疗前沿, 2012, 7(11): 56-57. DOI: 10.3969/j.issn.1673-5552.2012.11.0034.
|
[4] |
付景珂, 唐艳辉, 赵霞. 弥可保穴位注射治疗后天性麻痹性斜视临床观察. 中国斜视与小儿眼科杂志, 2010, 18(2): 88-89,92. DOI: 10.3969/j.issn.1005-328X.2010.02.015.
|
[5] |
中国神经生长因子临床应用专家共识协作组. 神经生长因子(恩经复)临床应用专家共识. 中华神经医学杂志, 2012, 11(4):416-420.
|
[5] |
中国神经生长因子临床应用专家共识协作组. 神经生长因子(恩经复)临床应用专家共识. 中华神经医学杂志, 2012, 11(4):416-420.
|
[6] |
甘晓玲. 斜视疗效评价标准. 中国斜视与小儿眼科杂志, 1996,4(4): 3.
|
[7] |
张莹, 孔庆兰, 陈杰, 等. 麻痹性斜视183例临床分析. 国际眼科杂志, 2013, 13(2): 343-345. DOI: 10.3980/j.issn.1672-5123.2013.02.37.
|
[8] |
乔彤, 陈偕穗. 成人双眼复视117例临床分析. 中华眼视光学与视觉科学杂志, 2014, 16(1): 48-51. DOI: 10.3760/cma.j.issn.1674-845X.2014.01.011.
|
[6] |
甘晓玲. 斜视疗效评价标准. 中国斜视与小儿眼科杂志, 1996,4(4): 3.
|
[7] |
张莹, 孔庆兰, 陈杰, 等. 麻痹性斜视183例临床分析. 国际眼科杂志, 2013, 13(2): 343-345. DOI: 10.3980/j.issn.1672-5123.2013.02.37.
|
[8] |
乔彤, 陈偕穗. 成人双眼复视117例临床分析. 中华眼视光学与视觉科学杂志, 2014, 16(1): 48-51. DOI: 10.3760/cma.j.issn.1674-845X.2014.01.011.
|
[9] |
袁静. 获得性麻痹性斜视病因分析. 中国煤炭工业医学杂志,2011, 14(9): 1292-1294.
|
[10] |
程洋, 薛山, 周蓓清. 甲钴胺穴位注射治疗外伤性动眼神经麻痹的疗效观察. 中国实用神经疾病杂志, 2016, 19(12): 118-119. DOI: 10.3969/j.issn.1673-5110.2016.12.076.
|
[11] |
张晓辉, 王峰, 熊蕾. 比较甲钴胺不同给药途径治疗后天性眼肌麻痹的疗效. 国际眼科杂志, 2011, 11(9): 1632-1633. DOI:10.3969/j.issn.1672-5123.2011.09.046.
|
[9] |
袁静. 获得性麻痹性斜视病因分析. 中国煤炭工业医学杂志,2011, 14(9): 1292-1294.
|
[10] |
程洋, 薛山, 周蓓清. 甲钴胺穴位注射治疗外伤性动眼神经麻痹的疗效观察. 中国实用神经疾病杂志, 2016, 19(12): 118-119. DOI: 10.3969/j.issn.1673-5110.2016.12.076.
|
[11] |
张晓辉, 王峰, 熊蕾. 比较甲钴胺不同给药途径治疗后天性眼肌麻痹的疗效. 国际眼科杂志, 2011, 11(9): 1632-1633. DOI:10.3969/j.issn.1672-5123.2011.09.046.
|
[12] |
Tanaka H. Old or new medicine? Vitamin B12 and peripheral nerve neuropathy. Brain Nerve, 2013, 65(9): 1077-1082.
|
[13] |
刘素江, 韩惠芳, 王世焕, 等. 先天性上斜肌麻痹性斜视患儿眼外肌NGF、GAP-43表达变化及意义. 山东医药, 2017,57(14): 98-100. DOI: 10.3969/j.issn.1002-266X.2017.14.031.
|
[14] |
Garcia TB, Hollborn M, Bringmann A. Expression and signaling of NGF in the healthy and injured retina. Cytokine Growth Factor Rev, 2017, 34: 43-57. DOI: 10.1016/j.cytogfr.2016.11.005.
|
[15] |
Roberti G, Mantelli F, Macchi I, et al. Nerve growth factor modulation of retinal ganglion cell physiology. J Cell Physiol,2014, 229(9): 1130-1133. DOI: 10.1002/jcp.24573.
|
[16] |
赵明. NGF对视神经挫伤患者视力和VEP的影响及安全性分析. 国际眼科杂志, 2018, 18(2): 316-318. DOI: 10.3980/j.issn.1672-5123.2018.2.28.
|
[17] |
Mesentier-Louro LA, De Nicolò S, Rosso P, et al. Time-dependent nerve growth factor signaling changes in the rat retina during optic nerve crush-induced degeneration of retinal ganglion cells. Int Jm Mol Sci, 2017, 18(1). pii: E98. DOI: 10.3390/ijms18010098.
|
[18] |
张颖, 张慧芝, 张英杰. 复方樟柳碱联合鼠神经生长因子治疗缺血性视神经病变临床观察. 中国实用神经疾病杂志, 2017,20(2): 36-38. DOI: 10.3969/j.issn.1673-5110.2017.02.014.
|
[19] |
黎玥, 徐建江. 神经生长因子对单纯疱疹病毒性角膜炎的治疗作用与机制. 中国眼耳鼻喉科杂志, 2017, 17(6): 436-440.DOI: 10.14166/j.issn.1671-2420.2017.06.016.
|
[20] |
焦毅, 梁凤鸣. 鼠神经生长因子治疗后天麻痹性斜视疗效观察. 中国现代医学杂志, 2017, 27(13): 67-69. DOI: 10.3969/j.issn.1005-8982.2017.13.013.
|
[12] |
Tanaka H. Old or new medicine? Vitamin B12 and peripheral nerve neuropathy. Brain Nerve, 2013, 65(9): 1077-1082.
|
[13] |
刘素江, 韩惠芳, 王世焕, 等. 先天性上斜肌麻痹性斜视患儿眼外肌NGF、GAP-43表达变化及意义. 山东医药, 2017,57(14): 98-100. DOI: 10.3969/j.issn.1002-266X.2017.14.031.
|
[14] |
Garcia TB, Hollborn M, Bringmann A. Expression and signaling of NGF in the healthy and injured retina. Cytokine Growth Factor Rev, 2017, 34: 43-57. DOI: 10.1016/j.cytogfr.2016.11.005.
|
[15] |
Roberti G, Mantelli F, Macchi I, et al. Nerve growth factor modulation of retinal ganglion cell physiology. J Cell Physiol,2014, 229(9): 1130-1133. DOI: 10.1002/jcp.24573.
|
[16] |
赵明. NGF对视神经挫伤患者视力和VEP的影响及安全性分析. 国际眼科杂志, 2018, 18(2): 316-318. DOI: 10.3980/j.issn.1672-5123.2018.2.28.
|
[17] |
Mesentier-Louro LA, De Nicolò S, Rosso P, et al. Time-dependent nerve growth factor signaling changes in the rat retina during optic nerve crush-induced degeneration of retinal ganglion cells. Int Jm Mol Sci, 2017, 18(1). pii: E98. DOI: 10.3390/ijms18010098.
|
[18] |
张颖, 张慧芝, 张英杰. 复方樟柳碱联合鼠神经生长因子治疗缺血性视神经病变临床观察. 中国实用神经疾病杂志, 2017,20(2): 36-38. DOI: 10.3969/j.issn.1673-5110.2017.02.014.
|
[19] |
黎玥, 徐建江. 神经生长因子对单纯疱疹病毒性角膜炎的治疗作用与机制. 中国眼耳鼻喉科杂志, 2017, 17(6): 436-440.DOI: 10.14166/j.issn.1671-2420.2017.06.016.
|
[20] |
焦毅, 梁凤鸣. 鼠神经生长因子治疗后天麻痹性斜视疗效观察. 中国现代医学杂志, 2017, 27(13): 67-69. DOI: 10.3969/j.issn.1005-8982.2017.13.013.
|
|
|
|